Alcyone Lifesciences Announces Broad Strategic Collaboration with Roche in the Field of Intrathecal Therapies
LOWELL, Mass., Dec. 20, 2018 /PRNewswire/ -- Alcyone Lifesciences, Inc., a leader in breakthrough technologies to treat complex neurological and oncological conditions through the company's proprietary advanced precision delivery platform, announced that it has entered into a broad strategic collaboration with Roche (F. Hoffmann-La Roche Ltd), to further advance Alcyone's market-leading position in cutting-edge precision drug delivery while providing Roche a unique opportunity to optimize intrathecal therapies and develop novel antisense oligonucleotide treatment options for patients with neurological disorders.
"We are delighted to announce this strategic collaboration with the Roche neuroscience group, which represents significant potential for patients with neurological conditions," stated PJ Anand, Alcyone's chief executive officer. "We believe our intelligent intrathecal delivery platform will help to bring transformative disease-modifying therapies to help patients with severe central nervous system (CNS) conditions. This collaboration is another clear validation that Alcyone addresses a significant unmet need within biopharma's therapy development pipelines."
About Alcyone Lifesciences, Inc.
Alcyone Lifesciences, based in Lowell, Massachusetts, is a privately-held biotechnology company passionately committed to applying engineering and science in the field of neurosciences and oncology to enable transformative therapies. For more information, please visit www.alcyonels.com
Contact
Alcyone Lifesciences, Inc.
PJ Anand
Chief Executive Officer
978-709-1946
info@alcyonels.com
SOURCE Alcyone Lifesciences, Inc.
